Quantcast

Industry news that matters to you.  Learn more

BG Medicine Announces FDA Clearance of its Galectin-3 Test for Use in Patients with Chronic HF

BG Medicine, Inc., a U.S.-based life sciences company, announced today that the U.S. Food and Drug Administration has cleared the company’s Galectin-3 test for use in conjunction with clinical evaluation as an aid to assess the prognosis of patients diagnosed with chronic heart failure. This marks the first time the FDA has cleared a test to measure galectin-3 blood levels, and is the first novel cardiac test cleared by the FDA in five years.

Creatine Kinase-MB Wins at Predicting Cardiac Outcomes

Myocardium specific creatine kinase levels appear to provide a better prognosis of long-term outcomes for elective heart surgery patients than do measures of troponin, according to a prospective study.

Multiple biomarker index useful only in asymptomatic patients with mild atherosclerosis

A multiple biomarker index, one that includes markers of inflammation, is only modestly associated with increased risks of coronary heart disease and cardiovascular disease in asymptomatic patients, according to the results of a new study [1]. The increased risk of events for patients with a biomarker score above the median occurs mainly in those with a mild amount of existing atherosclerosis, according to investigators.